ABUS Arbutus Biopharma Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ABUS [NASD]

Arbutus Biopharma Corporation

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.68	Insider Own	2.00%	Shs Outstand	67.68M	Perf Week	-21.51%
Market Cap	272.07M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-1.25%	Shs Float	48.20M	Perf Month	81.48%
Income	-155.70M	PEG	-	EPS next Q	-0.23	Inst Own	38.60%	Short Float	1.59%	Perf Quarter	86.41%
Sales	6.80M	P/S	40.01	EPS this Y	-137.80%	Inst Trans	-0.08%	Short Ratio	0.09	Perf Half Y	4.57%
Book/sh	-0.99	P/B	-	EPS next Y	15.40%	ROA	-120.30%	Target Price	5.00	Perf Year	133.33%
Cash/sh	1.07	P/C	3.20	EPS next 5Y	-	ROE	416.80%	52W Range	0.82 - 9.02	Perf YTD	23.38%
Dividend	-	P/FCF	-	EPS past 5Y	-9.90%	ROI	203.20%	52W High	-61.97%	Beta	3.16
Dividend %	-	Quick Ratio	21.90	Sales past 5Y	-16.70%	Gross Margin	-	52W Low	317.58%	ATR	0.66
Employees	80	Current Ratio	21.90	Sales Q/Q	114.30%	Oper. Margin	-	RSI (14)	50.35	Volatility	12.08% 26.95%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	46.60%	Profit Margin	-	Rel Volume	0.53	Prev Close	3.56
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 07 BMO	Payout	-	Avg Volume	8.74M	Price	3.43
Recom	2.30	SMA20	-9.08%	SMA50	29.15%	SMA200	52.71%	Volume	4,622,907	Change	-3.65%

Jul-27-20

Resumed

JMP Securities

Mkt Outperform

$10 → $8

Jul-24-20

Downgrade

Robert W. Baird

Outperform → Neutral

May-19-20

Upgrade

Wedbush

Neutral → Outperform

Mar-06-20

Upgrade

Chardan Capital Markets

Neutral → Buy

Feb-20-20

Initiated

Robert W. Baird

Outperform

Feb-05-20

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$10

Oct-07-19

Reiterated

B. Riley FBR

Buy

$7 → $3

Oct-04-19

Downgrade

Chardan Capital Markets

Buy → Neutral

Oct-16-18

Upgrade

B. Riley FBR

Neutral → Buy

$11.50 → $9

Oct-15-18

Upgrade

Wedbush

Underperform → Neutral

Oct-12-18

Reiterated

Chardan Capital Markets

Buy

$12 → $6.50

Jul-06-18

Downgrade

B. Riley FBR, Inc.

Buy → Neutral

$9 → $9

Mar-19-18

Resumed

Chardan Capital Markets

Buy

$8.25

Mar-19-18

Downgrade

Wedbush

Outperform → Neutral

$9 → $6

Jan-05-18

Initiated

B. Riley FBR, Inc.

Buy

$10

Apr-04-17

Upgrade

Chardan Capital Markets

Neutral → Buy

$3 → $6

Feb-01-17

Reiterated

Wedbush

Outperform

$13 → $10

Dec-13-16

Downgrade

Chardan Capital Markets

Buy → Neutral

$4 → $3

Nov-30-16

Upgrade

Chardan Capital Markets

Neutral → Buy

Oct-14-16

Upgrade

Chardan Capital Markets

Sell → Neutral

Aug-12-20 11:27AM	ROCE Insights For Arbutus Biopharma Benzinga
Aug-10-20 11:30AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? Zacks
Aug-07-20 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates Zacks -13.04%
07:50AM	Recap: Arbutus Biopharma Q2 Earnings Benzinga
07:30AM	Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-20 08:00AM	Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +11.47%
Jul-31-20 12:30PM	Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know Zacks -11.40%
Jul-29-20 06:00PM	1 Reason to Sell Moderna Now Motley Fool
08:00AM	Arbutus to Report Second Quarter 2020 Financial Results GlobeNewswire
Jul-27-20 12:31PM	Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know Zacks -9.98%
Jul-24-20 11:52PM	Moderna says patent ruling not to affect COVID-19 vaccine development Reuters -20.00%
03:31PM	Moderna Lost a Patent Case and the Stock Is Slipping Barrons.com
12:57PM	Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications Motley Fool
11:25AM	How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program Benzinga
08:59AM	Moderna's stock falls the day after 'disappointing' patent ruling MarketWatch
07:15AM	The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs Benzinga
12:38AM	Moderna loses challenge to Arbutus patent on vaccine technology Reuters
12:02AM	Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent Benzinga
Jul-23-20 05:39PM	Moderna Dives On Patent Battle That Could Jeopardize Coronavirus Vaccine Investor's Business Daily +119.86%
Jun-15-20 08:18PM	Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy? Insider Monkey +6.36%
May-27-20 08:00AM	Arbutus to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-20 01:18PM	Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More Zacks
May-19-20 11:11AM	P/E Ratio Insights for Arbutus Biopharma Benzinga +23.53%
May-18-20 04:05PM	Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg GlobeNewswire -10.95%
06:05AM	Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically Simply Wall St.
May-15-20 11:04AM	Why Arbutus (ABUS) Stock Might be a Great Pick Zacks +14.13%
09:15AM	Arbutus' Shares March Higher, Can It Continue? Zacks
May-14-20 02:22PM	3 Strong Buy Penny Stocks With Triple-Digit Upside TipRanks +8.24%
May-12-20 08:00AM	Arbutus to Present at UBS Virtual Global Healthcare Conference GlobeNewswire +14.58%
May-11-20 11:19AM	Moving Average Crossover Alert: Arbutus Biopharma Zacks +6.67%
07:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:12AM	Arbutus Biopharma: Q1 Earnings Insights Benzinga
06:00AM	Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections GlobeNewswire
May-04-20 08:00AM	Arbutus to Report First Quarter 2020 Financial Results GlobeNewswire +13.08%
Apr-27-20 12:32PM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know Zacks
Mar-31-20 08:47AM	Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't? Zacks -9.82%
06:16AM	The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Mar-27-20 08:02AM	The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance Benzinga -46.46%
Mar-26-20 04:05PM	Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B GlobeNewswire +5.12%
Mar-05-20 08:55AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:30AM	Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update GlobeNewswire
Feb-27-20 12:30PM	Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks +10.71%
08:00AM	Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
Feb-10-20 08:00AM	Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer GlobeNewswire
Jan-02-20 05:05AM	Does The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Price Tend To Follow The Market? Simply Wall St. +5.76%
Dec-30-19 10:08AM	Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock Zacks +9.64%
Dec-27-19 09:04AM	Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down Zacks
Dec-19-19 03:50PM	Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode Insider Monkey
Nov-06-19 09:35AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM	Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 07:13AM	We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-30-19 10:33AM	Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
07:30AM	Arbutus to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-10-19 02:59PM	Bucks biopharm firm halts study of potential hepatitis B cure American City Business Journals
Oct-04-19 07:32AM	The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga -28.67%
Oct-03-19 04:05PM	Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Globenewswire Test
04:05PM	Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B GlobeNewswire
Sep-26-19 07:30AM	Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire -6.25%
Sep-19-19 06:17AM	Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop? Simply Wall St.
Aug-20-19 04:05PM	Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors GlobeNewswire
Aug-06-19 07:30AM	Arbutus to Participate at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM	Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-29-19 07:30AM	Arbutus to Report Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 10:34AM	Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-15-19 04:05PM	Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B GlobeNewswire
Jul-04-19 04:09PM	Heres What Hedge Funds Think About Arbutus Biopharma Corp (ABUS) Insider Monkey
Jul-03-19 07:31AM	The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief Benzinga -5.26%
Jul-02-19 04:01PM	Arbutus Sells Part of its ONPATTRO (patisiran) Royalty Interest to OMERS GlobeNewswire
Jun-21-19 09:20AM	Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up Zacks -6.78%
Jun-20-19 07:30AM	Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729 GlobeNewswire +37.21%
Jun-17-19 07:30AM	Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. GlobeNewswire +24.66%
Jun-13-19 08:30AM	Arbutus to Participate at JMP Securities Life Sciences Conference GlobeNewswire
May-22-19 12:56PM	Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO? Simply Wall St. -10.30%
May-13-19 08:30AM	Arbutus to Present at Upcoming May 2019 Conferences GlobeNewswire -6.38%
May-06-19 05:15PM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:45PM	Arbutus: 1Q Earnings Snapshot Associated Press
04:01PM	Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-29-19 08:30AM	Arbutus to Report First Quarter 2019 Financial Results GlobeNewswire
Apr-25-19 10:33AM	Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks -5.84%
Apr-11-19 09:27AM	4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-08-19 08:37AM	Top Ranked Momentum Stocks to Buy for April 8th Zacks
Apr-04-19 03:03PM	Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last? Simply Wall St. +6.22%
Mar-07-19 10:26PM	Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM	Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives GlobeNewswire
Feb-28-19 08:30AM	Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update GlobeNewswire
Feb-04-19 07:35AM	Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-19 10:13AM	Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register? Simply Wall St.
Dec-23-18 03:40AM	Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)? Insider Monkey
Dec-11-18 07:55AM	New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-08-18 10:03PM	Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy? Insider Monkey
Dec-05-18 11:20AM	Why Arbutus Biopharma Corporations (NASDAQ:ABUS) CEO Pay Matters To You Simply Wall St.
Nov-26-18 04:41PM	Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors GlobeNewswire -5.60%
Nov-21-18 08:41AM	Options Traders Expect Huge Moves in Arbutus (ABUS) Stock Zacks +5.17%
Nov-07-18 04:01PM	Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-18 08:30AM	Arbutus to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-22-18 08:30AM	Arbutus Names New Members to its Board of Directors GlobeNewswire
Oct-19-18 08:25AM	New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-17-18 02:25PM	What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)? Simply Wall St.
Oct-10-18 10:23AM	Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks -23.83%

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McElhaugh Michael J.	Chief Business Officer	Jul 23	Sale	5.01	20,000	100,200	1,367,457	Jul 27 05:27 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience